PROTHENA CORPORATION PUBLIC LIMITED COMPANY Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $74.50 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2025-02-27
- 2024-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $74.50M.
- 2024-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $84.90M.
- 2024-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $102.60M.
- 2024-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $115.20M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2024-12-31 | $74.50M 10-K · filed 2025-02-27 |
| 2024-09-30 | $84.90M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $102.60M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $115.20M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $89.40M 10-K · filed 2024-02-22 |
| 2022-09-30 | $74.10M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $80.70M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $83.60M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $51.50M 10-K · filed 2022-02-25 |
| 2021-09-30 | $49.30M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $48.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $44.80M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $32.70M 10-K · filed 2021-02-26 |
| 2020-09-30 | $36.80M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $41.80M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $45.60M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $39.10M 10-K · filed 2020-03-03 |
| 2019-09-30 | $47.20M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $51.50M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $58.20M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $58.30M 10-K · filed 2019-03-15 |
| 2018-09-30 | $75.20M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $88.40M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |